News | October 05, 2009

Ovarian Cancer National Alliance Issues Practice Guidelines

October 5, 2009 - In a bold effort to provide women and their doctors with better information about how and when to take the necessary steps to obtain an early diagnosis for ovarian cancer, the Ovarian Cancer National Alliance has taken the lead in posting guidance for diagnoses on its web site (ovariancancer.org/diary).

The Interim Practice Guidance, endorsed by prominent specialists in the field of gynecologic cancer, marks the first time ovarian cancer diagnostic protocols have been made available to the public. In addition to the guidance, a Symptom Diary that helps women measure the persistency and severity of their symptoms (initially developed in the United Kingdom by Ovarian Cancer Action), has been reproduced in conjunction with the Gynecologic Cancer Foundation, with permission for use in the United States.

Annually, more than 15,000 women die from ovarian cancer, and survival rates have hovered at 40 percent for years, primarily due to the lack of a reliable early detection test, and that many of the symptoms often mimic other, less life-threatening problems.

Karen Orloff Kaplan, CEO of the Ovarian Cancer National Alliance believes this important information should be shared publicly to help women with ovarian cancer get diagnosed sooner. “Giving women the information they need to more effectively listen to their bodies and recognize the symptoms of ovarian cancer can help reduce the number of deaths from this hideous disease. By using the Symptom Diary and the Interim Practice Guidance, we believe that more lives can be saved.”
Barbara Goff, M.D. of the Seattle Cancer Care Alliance also endorsed the preparation and release of the guidance. “I think this guidance is important because the symptoms of ovarian cancer are very common and we all have them from time to time. This guidance summary provides information to practitioners and women about when symptoms may be concerning for ovarian cancer and what are the possible diagnostic tests that can be done if ovarian cancer is of concern.”
For more information: www.ovariancancer.org/diary

Related Content

Lunit Receives Korea MFDS Approval for Lunit Insight MMG
News | Artificial Intelligence | August 19, 2019
Lunit has announced Korea Ministry of Food and Drug Safety (MFDS) approval of its artificial intelligence (AI) solution...
Imago Systems Announces Collaboration With Mayo Clinic for Breast Imaging

Image courtesy of Imago Systems

News | Mammography | August 14, 2019
Image visualization company Imago Systems announced it has signed a know-how license with Mayo Clinic. The multi-year...
Artificial Intelligence Could Yield More Accurate Breast Cancer Diagnoses
News | Artificial Intelligence | August 13, 2019
University of California Los Angeles (UCLA) researchers have developed an artificial intelligence (AI) system that...
Lake Medical Imaging Selects Infinitt for Multi-site RIS/PACS
News | PACS | August 09, 2019
Infinitt North America will be implementing Infinitt RIS (radiology information system)/PACS (picture archiving and...
Volpara to Distribute Screenpoint Medical's Transpara AI Solution
News | Breast Imaging | August 02, 2019
Volpara Solutions and ScreenPoint Medical BV signed an agreement under which Volpara will sell ScreenPoint's Transpara...
Ikonopedia Releases Automated Combined Reporting Package at AHRA
News | Mammography Reporting Software | July 26, 2019
Ikonopedia showcased its recently released Automated Combined Reporting package and its entire suite of structured...
Hologic Partners With MagView to Develop Unifi EQUIP Solution
Technology | Mammography Reporting Software | July 25, 2019
Hologic announced a partnership with mammography information solutions provider MagView to develop Unifi EQUIP, an...
Fujifilm Releases Tomosynthesis Biopsy Option for Aspire Cristalle Mammography System
Technology | Breast Biopsy Systems | July 24, 2019
Fujifilm Medical Systems U.S.A. Inc. recently expanded its breast imaging solutions with the launch of its...
IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017.

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017, and who had health records for at least one year prior to the mammogram. The algorithm was trained on 9,611 mammograms. Image courtesy of Radiology.

Feature | Artificial Intelligence | July 19, 2019 | Michal Chorev
Breast cancer is the global leading cause of cancer-related deaths in women, and the most commonly diagnosed cancer...
Paragon Biosciences Launches Qlarity Imaging to Advance FDA-cleared AI Breast Cancer Diagnosis System

Qlarity Imaging’s software is used to assist radiologists in the assessment and characterization of breast lesions. Imaging features are synthesized by an artificial intelligence algorithm into a single value, the QI score, which is analyzed relative to a database of reference abnormalities with known ground truth. Image courtesy of Business Wire.

Technology | Artificial Intelligence | July 18, 2019
Paragon Biosciences LLC announced the launch of its seventh portfolio company, Qlarity Imaging LLC, which was founded...